Loading...

Gelesis Holdings, Inc.

GLSNYSE
Healthcare
Biotechnology
$0.16
$0.00(0.00%)

Gelesis Holdings, Inc. (GLS) Company Profile & Overview

Explore Gelesis Holdings, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Gelesis Holdings, Inc. (GLS) Company Profile & Overview

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

SectorHealthcare
IndustryBiotechnology
CEOMr. Yishai Zohar

Contact Information

617 456 4718
501 Boylston Street, Boston, MA, 02116

Company Facts

93 Employees
IPO DateJan 14, 2022
CountryUS

Frequently Asked Questions

;